Chronic pulmonary complications associated with toxic epidermal necrolysis: Report of a severe case with anti-Ro/SS-A and a review of the published work-Reference-Cited by-同舟云学术

Chronic pulmonary complications associated with toxic epidermal necrolysis: Report of a severe case with anti-Ro/SS-A and a review of the published work

Published:2006-09 Issue:9 Volume:33 Page:616-622
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

KAMADA Noriaki,KINOSHITA Kyoko,TOGAWA Yaei,KOBAYASHI Takashi,MATSUBARA Hiroshi,KOHNO Masakazu,IGARI Hidetoshi,KURIYAMA Takayuki,NAKAMURA Masataka,HIRASAWA Hiroyuki,SHINKAI Hiroshi

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1346-8138.2006.00142.x/fullpdf

Reference28 articles.

1. Toxic epidermal necrolysis

2. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme

3. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity

4. Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Are Induced by Soluble Fas Ligand

5. Toxic epidermal necrolysis (Lyell syndrome)

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe Cutaneous Adverse Reactions to Drugs;Rook's Textbook of Dermatology;2024-03-19

2. Topical Betamethasone Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Ocular Involvement in the Acute Phase;American Journal of Ophthalmology;2023-09

3. Disease severity and status in Stevens–Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs;Frontiers in Medicine;2022-09-12

4. Comment on “Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma”;Contact Dermatitis;2022-07-10

5. Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics;Frontiers in Pharmacology;2022-04-20